Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.